Stocks Health care SNDX
NASDAQ · Health careSyndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc brought in $289.4M of revenue over the twelve months to September 30, 2026, up 159.5% from a year earlier. It posted a net loss of $209.5M. In fiscal 2025 capital spending exceeded operating cash flow by $323.2M. At September 30, 2026 it held $135.9M in cash against $350M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Syndax Pharmaceuticals Inc
- Net worth
- Syndax Pharmaceuticals Inc has a market value (market cap) of $865.3M at the latest share price, and shareholders' equity of -$17.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $172.4M (+627.8% year on year), with a net loss of $285.4M. Over the 12 months to September 30, 2026: revenue $289.4M, net loss $209.5M.
- Cash flow
- In fiscal 2025 operations used $323M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Syndax Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Syndax Pharmaceuticals Inc does
Syndax Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SNDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $172.4M | -$285.4M | -$3.29 | -$323.2M |
| 2024 | $23.7M | -$318.8M | -$3.72 | -$274.9M |
| 2023 | $0 | -$209.4M | -$2.98 | -$160.6M |
| 2022 | $0 | -$149.3M | -$2.46 | -$133.7M |
| 2021 | $139.7M | $24.9M | $0.46 | $29M |
| 2020 | $1.5M | -$73.2M | -$1.87 | -$71.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SNDX ranks in Health care
Latest SEC filings
What Syndax Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 82% to $83.3M versus the same quarter last year; diluted EPS -$0.55 versus -$0.70.
- November 2, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 92% to $72.8M versus the same quarter last year; diluted EPS -$0.55 versus -$0.83.
- August 4, 2026
- July 14, 2026Other event 8-K
- June 10, 2026
- June 10, 2026
- June 4, 2026Additional proxy material DEFA14A
- June 4, 2026
Insider trades
What the people running Syndax Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $113.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 29, 2026 | Podlesak DennisDirector | Exercised options | 8,000 | $94.5K |
| October 29, 2026 | Podlesak DennisDirector | Soldpre-planned (10b5-1) | 8,000 | $113.7K |
| July 8, 2026 | Metzger Michael AChief Executive Officer, Director | Exercised options | 32,375 | $206.6K |
| July 8, 2026 | Metzger Michael AChief Executive Officer, Director | Soldpre-planned (10b5-1) | 32,375 | $784.8K |
| June 12, 2026 | Botwood Nicholas A.J.Head of R&D, CMO | Exercised options | 31,235 | $431.7K |
| June 12, 2026 | Botwood Nicholas A.J.Head of R&D, CMO | Soldpre-planned (10b5-1) | 31,235 | $566.6K |
| June 11, 2026 | Botwood Nicholas A.J.Head of R&D, CMO | Exercised options | 22,515 | $311.2K |
| June 11, 2026 | Botwood Nicholas A.J.Head of R&D, CMO | Soldpre-planned (10b5-1) | 34,280 | $617K |
Who owns SNDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Kynam Capital Management, LP13G, passive with 2 related filers | 9.98% | February 14, 2025 |
| Vanguard Capital Management13G, passive | 5.05% | April 30, 2026 |
Largest institutional holders
Insiders
9 insiders reported holding 1,428,743 shares in total, about $13.8M at the last price.
| Holder | Shares |
|---|---|
| Metzger Michael AChief Executive Officer, Director | 484,843 |
| Podlesak DennisDirector | 239,763 |
| Goldan Keith A.Chief Financial Officer | 139,252 |
| Katkin KeithDirector | 124,000 |
| Jarrett JenniferDirector | 114,000 |
| Legault PierreDirector | 114,000 |
| Huber Martin H. Jr.Director | 103,000 |
| Botwood Nicholas A.J.Head of R&D, CMO | 60,885 |
| Rizo AleksandraDirector | 49,000 |
Questions about SNDX
What does Syndax Pharmaceuticals Inc do?
Syndax Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as SNDX. Its shares trade on NASDAQ under the ticker SNDX.
What is Syndax Pharmaceuticals Inc's net worth?
Syndax Pharmaceuticals Inc has a market value (market cap) of $865.3M at the latest share price, and shareholders' equity of -$17.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Syndax Pharmaceuticals Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $209.5M on revenue of $289.4M.
How much revenue does Syndax Pharmaceuticals Inc make?
Over the twelve months to September 30, 2026 Syndax Pharmaceuticals Inc reported revenue of $289.4M. That is 159.5% more than a year earlier.
When did Syndax Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026.
When is Syndax Pharmaceuticals Inc's next earnings report?
Syndax Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SNDX with
Follow SNDX
Get an email when Syndax Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Syndax Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.